It will also be regulating prices domestically, sort of. Trump mentioned introducing the "Favored Nations" clause. He just doesn't want to rely on that entirely

It will also be regulating prices domestically, sort of. Trump mentioned introducing the "Favored Nations" clause. He just doesn't want to rely on that entirely. Regulating prices domestically == letting some idiot who had never run a business decide what products should cost. It's a dead end. Favored nations basically says you can't sell the product to us at a price that's higher you're charging your other customers, which, to me, makes more sense. You retain pricing flexibility, but not too much of it. I don't see why a European should pay less for a drug than a US person, who likely partially funded the early stages of development of that drug with her federal taxes. Another issue is that even _generic_ drugs are often wildly overpriced in the US. Canada (or some other country, such as e.g. India, which has a strong pharma industry) could pretty easily just make more of them and exert downward price pressure. What's unfolding before us here is historic. Previous administrations were all too beholden to Big Pharma to even contemplate any of this.